Results 211 to 220 of about 365,877 (337)

A lncRNA and radiomics-based model for predicting the response of non-small cell lung cancer to chemo- and radio-therapy. [PDF]

Sci Rep
Ye F, Yin Y, Wang J, Wang J, Yang J, Zhang J, Zhang Y, Qi J, Zhu Q, Zhang Y, Ji H, Hu Z, Hong B, Wang H.   +13 more
europepmc   +1 more source

Protein glycosylation in lung cancer from a mass spectrometry perspective

Mass Spectrometry Reviews, EarlyView.
Abstract Lung cancer is a severe disease for which better diagnostic and therapeutic approaches are urgently needed. Increasing evidence implies that aberrant protein glycosylation plays a crucial role in the pathogenesis and progression of lung cancer.
Mirjam Balbisi, Simon Sugár, Lilla Turiák   +2 more
wiley   +1 more source

Metformin-Repressed miR-381-YAP-Snail Axis Activity Disrupts NSCLC Growth and Metastasis

, 2019
Dan Jin, Jiwei Guo, Yan Wu, Weiwei Chen, Jing Du, Lijuan Yang, Xiaohong Wang, Kaikai Gong, Juanjuan Dai, Shuang Miao, Xuelin Li, Guoming Su   +11 more
openalex   +1 more source

Data from MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLC

, 2023
Maroof Alam, Rehan Ahmad, Hasan Rajabi, Donald Küfe   +3 more
openalex   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

Table_2_PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China.doc

, 2021
Qiao Liu (346535), Xia Luo (169127), Zhen Zhou (184390), Liubao Peng (300794), Lidan Yi (495042), Xiaomin Wan (300793), Chongqing Tan (387068), Xiaohui Zeng (300791)   +7 more
openalex   +2 more sources

Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer [PDF]

, 2017
et al,, Govindan, Ramaswamy
core   +1 more source

Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detection. [PDF]

BMJ Oncol
Jimenez-Munarriz B, Urtecho B, Rabey MR, Leighl NB.   +3 more
europepmc   +1 more source

Radiotherapy and Immune System Interactions Historical Perspectives and Clinical Advancements

Molecular Carcinogenesis, EarlyView.
ABSTRACT Radiotherapy (RT) has evolved significantly since its inception from treating benign conditions to becoming a cornerstone of cancer treatment. This review examines the complex interactions between RT and the immune system, highlighting its diverse effects on various immune cell populations, and exploring emerging strategies to enhance ...
Safiy Yahia, Ayman J. Oweida, Houda Bahig, Daniel Taussky   +3 more
wiley   +1 more source

Data from Abnormalities of the <i>TITF-1</i> Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis

, 2023
Ximing Tang, Humam Kadara, Carmen Behrens, Diane D. Liu, Yun Xiao, David C. Rice, Adi F. Gazdar, Junya Fujimoto, César A. Moran, Marileila Varella-Garcia, J Jack Lee, Waun Ki Hong, Ignacio I. Wistuba   +12 more
openalex   +1 more source